Research studies conducted with cancer patients are called clinical trials. As a cancer patient, you may take part in a clinical trial. Please see the links below for current open trials at UC San Francisco.
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Marin Pollak (415) 215-4475: [email protected]
Currently enrolling patients with BRAFV600E mutations only
Colorectal Non-Therapeutic Studies
CC#21456: Optimizing Intervention Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors (Tools To Be Fit)
Contact: Evelyn Montenegro (415) 218-8398: [email protected]
https://toolstobefit.eurekaplatform.org/
CC#224523: Optimization of Adaptive Text Messages for Cancer Survivors II (OATS II)
Contact: Evelyn Montenegro (415) 218-8398: [email protected]
CC#134510: GIMP: Molecular Profiling in Gastrointestinal Malignancies
Contact: Insiyah Merchant (415) 205-8117: [email protected]
For information on Early Phase clinical trials not listed please contact:
[email protected]
AMC095: A Phase 1 Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
Contact: Suzannah Henderson, [email protected]
CC#19958: First-In-Human, Open-Label, Phase I Dose Escalation and Cohort Expansion Study of BB-1701 in Locally Advanced/Metastatic Her2 Expressing Solid Tumors
Contact: Tony Han, [email protected]
CC#20958: A Phase 1 Study of ERK1/2 Inhibitor JSI-1187 Administered as Monotherapy and in Combination with Dabrafenib for the treatment of Advanced Solid Tumors with MAPK Pathway Mutations
Contact: Zach Schoenherr, [email protected]
CC#21952: A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation
Contact: Jaden Sanders, [email protected]
CC#21953: A Phase 1a/1b Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Contact: Zach Schoenherr, [email protected]
CC#21955: A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
Contact: Tony Han, [email protected]
CC#21956: A Phase 1/1b, Open-Label, Multicenter, Dose-Escalation Study of RMC-5552 Monotherapy in Adult Subjects with Relapsed/Refractory Solid Tumors
Contact: Christian Kelly, [email protected]
Not currently enrolling
CC#21957: A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Contact: Jaden Sanders, [email protected]
CC#22951: A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors
Contact: Julian Aguilar, [email protected]
CC#22952: A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination With Toripalimabin Subjects With Advanced Solid Malignancies Including Lymphoma
Contact: Jaden Sanders, [email protected]
CC#22953: A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
Contact: Sukjun (James) Lee, [email protected]
CC#22958: A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
Contact: Sukjun (James) Lee, [email protected]
Not currently enrolling
CC#189510: Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies
Contact: Suzannah Henderson, [email protected]
CC#209511: A First-in-human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
Contact: Sukjun (James) Lee, [email protected]
CC#219511: An Open-label, Multicenter, Phase 1a/1b Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed, Refractory, or Newly Diagnosed Cancers
Contact: Christian Kelly, [email protected]
CC#219513: A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Contact: Kristy Tjokro, [email protected]
CC#229510: Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes
Contact: Suzannah Henderson, [email protected]
CC#229511: An Open-Label, Phase 1/1b, Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Contact: Anoushka Sharma, [email protected]
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Marin Pollak (415) 215-4475: [email protected]
Currently enrolling patients with cholangiocarcinoma, esophageal adenocarcinoma, squamous cell carcinoma, GEJ and gastric adenocarcinomas
CC# 214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Noor Ayat (415) 215-6489: [email protected]
Currently enrolling IO naïve patients with esophageal squamous cell carcinoma only
CC#22454: A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination with Hydroxychloroquine in Patients with Advanced Gastrointestinal Malignancies Harboring MAPK Pathway Mutations (BVD-523-HCQ)
Contact: Marin Pollak (415) 215-4475: [email protected]
Currently enrolling patients with cholangiocarcinoma, esophageal adenocarcinoma, squamous cell carcinoma, GEJ and gastric adenocarcinomas
CC#194522: Phase II Trial of Durvalumab (MEDI4736) with/without Tremelimumab for Advanced Hepatocellular Carcinoma after Palliative Hypofractionated Radiotherapy
Contact: Luchia Andemicael (415) 476-8099: [email protected]
CC#204517: A Phase 1b/2, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (Morpheus-Liver)
Contact: Jocelin Chen (415) 205-0182: [email protected]
Not currently enrolling (on hold for amendment; expected to open again in Summer 2024)
CC#214515: An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Multiple Solid Tumors
Contact: Noor Ayat (415) 215-6489: [email protected]
Currently enrolling IO naïve patients with esophageal squamous cell carcinoma only
CC#23458: A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab in Previously Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation
Contact: Jocelin Chen (415) 205-0182: [email protected]
CC#23457: A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen
Contact: Noor Ayat (415) 215-6489: [email protected]
CC#234510: A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors with Activating FGFR2 Gene Alterations (SURF-201)
Contact: Jocelin Chen (415) 205-0182: [email protected]
Hepatocellular and Biliary Tract Non-Therapeutic Studies
CC#124512: Banking of Human Biological Specimens for Hepatobiliary Cancer Research Studies: UCSF Hepatobiliary Tissue Bank and Registry
Contact: Jocelin Chen (415) 205-0182: [email protected]
CC#204516: A National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer (PLC)
Contact: Jocelin Chen (415) 205-0182: [email protected]
For information on Immunotherapy trials not listed please contact:
[email protected]
CC#16983: Biospecimen Acquisition Protocol for Analysis of Biomarkers in Cancers
Contact: Annie Deng (415) 307-5778: [email protected]
CC#21705: Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Contact: Marc McAuslen (415) 866-7481: [email protected]
CC#21708: A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Contact: Diamond Luong: [email protected]
CC#22703: A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
CC#22705: A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Contact: Harika Gopi: [email protected]
CC#187015: A Phase 2 Study of Perioperative Immunotherapy in Patients with Colorectal Cancer and Resectable Hepatic Metastases
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#217013: A Phase 1B, Open-Label, Dose-Escalation Study of the Safety of and Antigen-specific Immune Responses Elicited by VB10.NEO in Combination With Atezolizumab in Patients With Locally Advanced and Metastatic Tumors
Contact: Chris De Leon (415) 476-2958: [email protected]
Not currently enrolling
CC#217015: Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
Contact: Marissa Gin (415) 476-3816: [email protected]
CC#23706: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Contact: Kira Chan (415) 309-1810: [email protected]
A021901: Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors
Contact: Bryan Le (415) 218-7472: [email protected]
CC#22457: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Contact: Bryan Le (415) 218-7472: [email protected]
Enrollment is currently paused but we are accepting patients for the queue
Neuroendocrine Tumors Non-Therapeutic Studies
CC#194520: NET Voices: A Pilot Study Using a Web-Based Health Platform to Investigate Health-Related Quality of Life in Patients with Neuroendocrine Tumors
Contact: Farhana Moon: [email protected], [email protected]
https://enet.eurekaplatform.org/
CC#224513: Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms (PanNEN)
Contact: Bryan Le (415) 218-7472: [email protected]
CC#224514: Study of Maintenance Ivaltinostat plus Capecitabine or Capecitabine Monotherapy in Patients with Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on First Line FOLFIRINOX Chemotherapy
Contact: Sally Wu (415) 205-4812: [email protected]
A021806: A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Contact: Bryan Le (415) 218-7472: [email protected]
CC#23453: A Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
Contact: Eli Oh (415) 218-7153: [email protected]
CC#20451: THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients with Advanced Pancreatic Cancer
Contact: Banaz Shwan (415) 205-8214: [email protected]
CC#23456: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX versus mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
Contact: Insiyah Merchant (415) 205-8117: [email protected]
CC#214514: A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES-3)
Contact: Marin Pollak (415) 215-4475: [email protected]
Currently enrolling patients with BRAFV600E mutations only
Pancreatic Non-Therapeutic Studies
CC#224524: Pancreatic Cancer Early Detection (PRECEDE) Consortium
Contact: Gorang Gupta (415) 476-2874: [email protected]
CC#154520: Lifestyle and Outcomes after Gastrointestinal Cancer: A Prospective Cohort Study (LOGIC)
Contact: Eli Oh (415) 218-7153: [email protected]
CC#214511: Electronic Patient Reported Outcomes in Patients with Gastrointestinal Cancers at Risk for Unplanned ED Visits and Hospitalizations
Contact: Paige Steiding (415) 502-3310: [email protected]
A022106: Phase II/III Second-Line Nabplagem Vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)
Contact: Dalila Stanfield (415) 218-7153: [email protected]
CC#24452: A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-1200 in Participants with Advanced Solid Tumors
Contact: Dalila Stanfield (415) 218-7153: [email protected]
For information on Early Phase clinical trials not listed please contact:
[email protected]
For information on Immunotherapy trials not listed please contact:
[email protected]